Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review.
about
sameAs
Eating disorders in schizophrenia: implications for research and managementAlterations to melanocortinergic, GABAergic and cannabinoid neurotransmission associated with olanzapine-induced weight gainSecond-generation antipsychotics for anxiety disordersManagement of antipsychotic-related weight gainAripiprazole partial agonism at 5-HT2C: a comparison of weight gain associated with aripiprazole adjunctive to antidepressants with high versus low serotonergic activitiesReview of olanzapine in the management of bipolar disordersA roadmap to key pharmacologic principles in using antipsychoticsFrom the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinaseThe Treatment of Adult Bipolar Disorder with Aripiprazole: A Systematic ReviewIs There Room for Second-Generation Antipsychotics in the Pharmacotherapy of Panic Disorder? A Systematic Review Based on PRISMA GuidelinesConcerns about quetiapineMetabolic issues in patients affected by schizophrenia: clinical characteristics and medical managementUse of atypical antipsychotics in the elderly: a clinical reviewRandomized controlled trials in schizophrenia: opportunities, limitations, and trial design alternativesEpigenetic mechanisms in mood disorders: targeting neuroplasticityIs the prevalence of metabolic syndrome and metabolic abnormalities increased in early schizophrenia? A comparative meta-analysis of first episode, untreated and treated patientsCurrent Data on and Clinical Insights into the Treatment of First Episode Nonaffective Psychosis: A Comprehensive ReviewWhat can triumphs and tribulations from drug research in Alzheimer's disease tell us about the development of psychotropic drugs in general?An evaluation of the effects of the novel antipsychotic drug lurasidone on glucose tolerance and insulin resistance: a comparison with olanzapineAdverse Renal, Endocrine, Hepatic, and Metabolic Events during Maintenance Mood Stabilizer Treatment for Bipolar Disorder: A Population-Based Cohort StudyChronic Olanzapine Treatment Induces Disorders of Plasma Fatty Acid Profile in Balb/c Mice: A Potential Mechanism for Olanzapine-Induced Insulin ResistanceIntegrating multiple data sources (MUDS) for meta-analysis to improve patient-centered outcomes research: a protocol for a systematic reviewAllosteric modulation of the M1 muscarinic acetylcholine receptor: improving cognition and a potential treatment for schizophrenia and Alzheimer's diseaseMetabolic side-effects of the novel second-generation antipsychotic drugs asenapine and iloperidone: a comparison with olanzapine.Treatment of clozapine-associated obesity and diabetes with exenatide (CODEX) in adults with schizophrenia: study protocol for a pilot randomised controlled trialUsing internet enabled mobile devices and social networking technologies to promote exercise as an intervention for young first episode psychosis patients.Predicting implementation from organizational readiness for change: a study protocol.Monitoring and managing metabolic effects of antipsychotics: a cluster randomized trial of an intervention combining evidence-based quality improvement and external facilitation.Positive predictive value of a case definition for diabetes mellitus using automated administrative health data in children and youth exposed to antipsychotic drugs or control medications: a Tennessee Medicaid studyChange in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1QT interval duration and dispersion in children and adolescents treated with ziprasidone.Excessive weight gain after remission of depression in a schizophrenic patient treated with risperidone: case report.Genetics of antipsychotic treatment emergent weight gain in schizophrenia.Care for patients with severe mental illness: the general practitioner's role perspective.Fluoxetine and olanzapine combination therapy in treatment-resistant major depression: review of efficacy and safety data.Effects of typical and atypical antipsychotic drugs on gene expression profiles in the liver of schizophrenia subjects.Pharmacological management in children and adolescents with pervasive developmental disorder.The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statementsSafety and Tolerability of Adjunctive Aripiprazole in Major Depressive Disorder: A Pooled Post Hoc Analysis (studies CN138-139 and CN138-163).The effectiveness and safety of amisulpride in Chinese patients with schizophrenia who switch from risperidone or olanzapine: a subgroup analysis of the ESCAPE study.
P2860
Q21284525-0B7D477E-D8B8-4712-AC28-06DAAF79D08DQ21561008-469FC8A6-4C74-442D-97C9-3F36D2666CFCQ24235758-5051C432-2C17-4D63-8DC6-34B735766CFEQ24610124-F1D0C4A1-B115-4A4A-9A4D-EEF86DCC94F0Q24615556-1EBFE523-E825-45E9-8471-30934A7A8286Q24657398-30B4F431-BAEF-4C53-BC82-644F84AFB3D0Q24678461-1AC23201-C40D-43D4-8677-EF483A46BBD1Q24685521-755853D8-AF5D-4884-B4D4-C2D975F0DC92Q26748677-15D199C7-1E40-49B3-863E-B543000D9139Q26752771-8850078F-99AE-429F-B68C-21DD99541DEFQ26773288-955C67A9-FCDB-443A-AE6C-497933A3491BQ26783003-3E2CDE41-8FDF-44C8-AB68-8A865830ED37Q26827756-74CDAA34-0936-410A-B81E-3ED51DF9526BQ26863435-BFD43068-D7BD-4596-8745-B3D40B55A0FFQ27021810-16DB3B26-2316-4A1B-98CE-29E324282F26Q27027832-6EE054EF-B93A-4462-8A55-3D6F5298DF3BQ28079821-ED4DBAC9-3EE7-4F36-802C-6B7E6AF778B8Q28083481-B576599B-FD7C-4CFC-BAB7-42D56629C130Q28543222-FDFAF62B-5F17-4CC1-BD7D-5FFF14132CBEQ28553358-67759291-A150-47A3-882D-93C40E639C76Q28555023-4EC322EA-FBC9-4093-8040-58231280E541Q28608153-C9C2FD0F-CF84-4900-B596-9730C3E38116Q28660933-AF3438D6-CB86-4D09-A70F-2954514D315CQ30459096-DC0E57E0-DF41-41AF-A695-FD625A4DB584Q30489980-A038F5AF-352A-4894-8B32-A36F103C75E2Q30501289-A80A1B41-BC59-42A1-8AE9-83BF9DA1C580Q30503523-5BED9DBB-8DBF-4CC5-BA7D-B422334A6484Q30558767-BEDA5FF2-9F4A-4CB9-A1C3-E17DDD3F7890Q30559039-57CE919D-9FC3-4AE3-8185-4BB51DB50297Q31145823-CA23ED53-4E74-4830-BA27-81E1789AA849Q33159884-9499ADF7-B20F-40A6-9489-77D902598819Q33256430-62947E7C-F886-465A-A7E1-3A5BB5FA1CB6Q33257886-9ED4E2BB-FA0F-40D2-8D93-5C142809EA1BQ33440011-BD8EFA72-D4CF-412E-B742-DE53C5A1D66BQ33488312-B1B65FD7-7C5C-4AEC-A5EE-33CC1DEB905DQ33503890-D3391700-09CA-484C-8F87-3C0775F6C664Q33521748-4C50DEDE-0A0F-41FA-AD02-D76CFA5617D5Q33566124-0A7D4772-5CAD-47EC-8FEF-181D072D2C5EQ33587032-E9902BF2-62C7-4842-B165-AA8409ABA063Q33609974-A61B832E-590C-47CE-A5FA-B391776565BB
P2860
Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Second-Generation
@nl
Second-generation (atypical) a ...... mprehensive literature review.
@ast
Second-generation (atypical) a ...... mprehensive literature review.
@en
type
label
Second-Generation
@nl
Second-generation (atypical) a ...... mprehensive literature review.
@ast
Second-generation (atypical) a ...... mprehensive literature review.
@en
altLabel
Second-Generation (Atypical) Antipsychotics and Metabolic Effects
@en
prefLabel
Second-Generation
@nl
Second-generation (atypical) a ...... mprehensive literature review.
@ast
Second-generation (atypical) a ...... mprehensive literature review.
@en
P1433
P1476
Second-Generation (Atypical) Antipsychotics and Metabolic Effects
@en
Second-generation (atypical) a ...... mprehensive literature review.
@en
P2093
John W Newcomer
John W. Newcomer
P356
10.2165/00023210-200519001-00001
P433
Supplement 1
P577
2005-01-01T00:00:00Z
P5875
P6179
1002073185